The U.S. Food and Drug Administration (FDA) has approved a medication called dapagliflozin for adults with type 2 diabetes. This drug is approved for two main purposes. First, it can be used along with diet and exercise to help lower blood sugar levels. Second, and importantly, it is approved to reduce the risk of hospitalization for heart failure in people who also have known heart disease or several risk factors for it.
This approval is significant because it means doctors now have a single medication option that can address both blood sugar management and a major heart-related risk for many people with type 2 diabetes. It belongs to a class of drugs known as SGLT2 inhibitors.
The medication is not for everyone. The prescribing information includes specific guidance on dosing and notes that a person's kidney function should be checked before starting. It also advises that the drug may be paused before major surgeries. As with any new treatment option, this approval expands choices for healthcare providers.
It is important to remember that this is a prescription medication. The most important step for any patient is to have a conversation with their own doctor. A doctor can review an individual's full health history to determine if this new option is a suitable and safe part of their care plan.
